Session: 201. Granulocytes, Monocytes, and Macrophages: Poster II
Hematology Disease Topics & Pathways:
Adult, Diseases, Immune Disorders, Study Population, Clinically relevant, white blood cell disorders
Methods: We identified all adult inpatients (≥18 years) with an International Classification of Diseases (ICD) code for HLH in the province of Alberta, Canada from January 1999 to December 2019. Following independent chart review by two reviewers, cases were classified as positive, negative, or indeterminate cases of HLH. The HLH-2004 diagnostic criteria and H-score were determined for each case. The following performance characteristics of the diagnostic scoring systems were calculated: sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). C-statistic was calculated from the receiver operator curve (ROC) analysis.
Results: Data on 101 patients were collected. The median age was 46 years (range 18-88), 66 (65%) were male. Active malignancy within 6 months of presentation, infections, and autoimmune diseases were present in 31%, 36%, and 18%, respectively. Of the 96 patients who underwent bone marrow aspirate and biopsy, hemophagocytosis was present in 79 (82%). Using chart review as the gold standard, 89 (88%) patients were determined to have HLH, whereas 5 (5%) and 7 (7%) were reclassified as negative and indeterminate cases, respectively. 83 (82%) patients met ≥5 of the 8 HLH-2004 diagnostic criteria; using the HLH-2004 criteria missed 8 cases of HLH. The sensitivity and specificity of HLH-2004 criteria was 91.0% and 83.3%, respectively, with a PPV of 97.6% and an NPV of 55.6%. The median overall H-score was 238 (range 129-337). An H-Score cut-off of >169 (established as the optimal cut-off from the original derivation and validation paper) predicted HLH with a sensitivity of 95.5%, specificity of 16.7%, PPV of 89.5%, and NPV of 33.3%. The discriminatory power improved with an H-Score cut-off >210, with a sensitivity of 86.5%, specificity of 66.7%, PPV of 95.1%, and NPV of 40.0%. The c-statistics for the HLH-2004 criteria and the H-Score were 0.872 and 0.737, respectively. In the malignant subgroup, all patients fulfilled the HLH-2004 criteria and all were deemed to have HLH upon chart review. All but one had an H-Score >169, with a median H-Score of 238 (range 168-304) in the malignant group.
Conclusion: In our highly selected patient population with suspected HLH, the HLH-2004 had better discriminatory power than the H-Score, with a high sensitivity and specificity and excellent c-statistic >0.80. An H-Score cut-off of >169 was highly sensitive but non-specific in identifying adults with HLH. The validity and applicability of our study is limited by a high prevalence of chart-confirmed HLH in our sample. We are completing ongoing data collection to expand our validation study in a cohort of adults with hyperferritinemia who underwent bone marrow evaluation and/or sCD25 testing.
Disclosures: Sun: Sanofi: Other: Advisory board; Octapharma: Other: Advisory board; Octapharma: Research Funding; Novo Nordisk: Other: Advisory board; Pfizer: Other: Advisory board.
See more of: Oral and Poster Abstracts